Lv5
915 积分 2023-02-16 加入
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
4天前
已完结
Exploring the immunological effects of antibody–drug conjugates
6天前
已完结
Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trial
8天前
已完结
Lymph Node Metastasis Mapping after Neoadjuvant Immunochemotherapy in Gastric and Gastroesophageal Junction Cancer: A Pooled Analysis of 4 Prospective Clinical Trials
10天前
已完结
Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial
10天前
已完结
DOI: 10.1016/j.annonc.2026.09.015
11天前
已关闭
Perioperative Camrelizumab and Apatinib for High‐Risk Resectable Hepatocellular Carcinoma: A Phase II Study
12天前
已完结
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
17天前
已完结
Advances in Systemic Treatment of Breast Cancer
20天前
已完结
Cancer burden and control in China: landscape, trends and challenges
20天前
已完结
皖公网安备34019202002308
